Engflag

Telekast

Quick links to important sections

Telekast

Telekast_PL

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Telekast

The medicine Telekast is classified as a prescription-only drug designed for the ongoing, stable management of chronic conditions characterized by inflammatory processes in the airways and nasal passages.

Property Description
Active ingredient Montelukast Sodium
Form Oral tablet (film-coated, chewable), Oral granules
Pharmacological class Leukotriene Receptor Antagonist (LTRA)
Common use Maintenance therapy for airway and nasal inflammation
Origin Synthetic compound

Telekast: Definition and Pharmacological Class

Telekast contains the active ingredient Montelukast Sodium, a synthetically derived chemical substance that belongs to the pharmacological class of Leukotriene Receptor Antagonists (LTRAs). This classification is recognized for its role in modifying the inflammatory environment of the airways.

The LTRA classification defines the drug's mechanism as specifically targeting and blocking the action of cysteinyl leukotrienes (CysLTs), such as Leukotriene D4 (LTD4), which are potent inflammatory mediators released by the body.

This targeted approach, which involves selectively inhibiting the CysLT1 receptor, positions Montelukast as a crucial component of maintenance therapy aimed at controlling underlying inflammation, differentiating it from medications used for immediate, acute symptom relief.

Composition, Form, and General Therapeutic Role

Montelukast Sodium is an orally active compound formulated for systemic absorption and is administered through the mouth. The availability of a chewable tablet and oral granules marks a key feature of Montelukast formulations, allowing easier administration to adolescents and children who may not be able to swallow conventional tablets.

The active substance is incorporated into several solid oral dosage forms. Montelukast, as an LTRA, provides daily control of inflammation for its intended conditions. As a maintenance therapy, the core therapeutic role of the medication is to reduce the chronic inflammation within the respiratory and nasal mucosal tissues, serving to support a more consistent and stable breathing capacity over time.

Regulatory References

  1. NIH LiverTox

What side effects are possible with Telekast?

Possible Side Effects and Safety Information

The officially documented adverse reactions for Telekast (Montelukast) are categorized by regulatory agencies based on their frequency and the system or organ affected.

Documented Frequency and System Involvement

Adverse reactions are classified according to incidence rates established in regulatory documents:

  • Very Common: Upper respiratory infection.
  • Common: Headache, abdominal pain, diarrhea, nausea, vomiting, pyrexia (fever), rash, and elevated serum transaminases.
  • Uncommon: Hypersensitivity reactions, agitation, depression, insomnia, dizziness, and urticaria.

The most commonly affected System-Organ Classes (SOC) include Infections and Infestations, Nervous System Disorders, Gastrointestinal Disorders, and Skin and Subcutaneous Tissue Disorders.

Serious Adverse Reactions and Safety Constraints

Neuropsychiatric Events constitute a serious risk documented with a Boxed Warning in U.S. regulatory labeling. These events include symptoms such as suicidal ideation and behavior, depression, anxiety, and agitation, and may occur during or after the initiation of treatment. Other serious events noted in the regulatory profile are rare cases of hepatitis and systemic eosinophilia with vasculitis (Churg-Strauss Syndrome).

Telekast is formally contraindicated in individuals with known hypersensitivity to the active substance or any component of the formulation. Furthermore, regulatory safety statements note that the drug should only be used during pregnancy and lactation when deemed clearly necessary, and safety in severe hepatic impairment has not been established.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents on Telekast (Montelukast Sodium) define the overdose profile based on clinical reports and post-marketing experience. Immediate medical attention is required upon the suspicion or occurrence of an overdose, regardless of the dose amount. It is mandated to contact a certified Poison Control Center immediately for professional guidance and instructions.

Documented Overdose Manifestations

Acute overdose reports, including instances up to 1000 mg in adults and high doses in pediatric patients, list symptoms that are generally consistent with the known safety profile of the medicine. The most frequently documented clinical manifestations in these reports include:

Symptom Cluster Specific Manifestations
Gastrointestinal Abdominal pain, Vomiting
Central Nervous System Somnolence (Drowsiness), Headache, Psychomotor hyperactivity
Other Thirst

Required Clinical Management

The official regulatory statement is that no specific antidote is known for Montelukast overdose. Consequently, the required management approach involves providing symptomatic and supportive treatment under medical supervision. This care may include the consideration of procedures such as gastric lavage, particularly if the ingestion was recent. It is further noted in the official documentation that it is unknown whether the active substance is dialyzable by either peritoneal dialysis or hemodialysis. Observation and monitoring for any signs of clinical deterioration are essential components of the required medical care.

Therapeutic Uses of Telekast

What Telekast Treats: Main Uses and Benefits

Telekast (Montelukast) is generally used as a long-term controller medication for managing inflammatory or irritative states in the airways and nasal passages. The medicine is applied across therapeutic domains where additional symptomatic support is needed for chronic conditions, including the prophylaxis and chronic treatment of asthma, the symptomatic relief of seasonal and perennial allergic rhinitis, and the acute prevention of exercise-induced bronchoconstriction (EIB).

Telekast is relevant in conditions characterized by periods of heightened symptoms. It helps address symptom clusters that create noticeable physiological strain, such as recurring wheezing, chest tightness, persistent coughing, and bothersome nasal congestion. This supportive benefit may assist with maintaining functional stability and contributes to easing the overall symptom load over time.

Quick Fact: Sustained Symptom Management

Telekast plays a role in managing both lower airway symptoms (asthma-related wheezing and coughing) and upper airway symptoms (allergic rhinitis-related nasal congestion and sneezing), providing supportive management across both respiratory domains for sustained symptom control.

Eligibility and Restrictions for Use

Who Can and Cannot Use Telekast?

Eligibility for Telekast (Montelukast Sodium) is strictly defined by regulatory authorities based on absolute prohibitions, age limitations, and specific physiological conditions. This medicine is intended only for chronic maintenance management and is not for immediate, acute relief.

Official Eligibility Restrictions

Classification Rule and Documentation
Absolute Contraindication Patients with known hypersensitivity to Montelukast Sodium or any component of the formulation are prohibited from use.
Prohibited Use (Scenario) The medicine is contraindicated for the treatment of acute asthma attacks (bronchospasm) or status asthmaticus.

Population Eligibility Rules

Telekast is approved for Adults and Adolescents (15 years and older) and for specific Pediatric Patients starting from 6 months of age, depending on the indication and formulation. Safety and efficacy are not established for infants under 6 months.

  • Organ Function: Use is permitted without dose adjustment for any degree of renal impairment or mild-to-moderate hepatic impairment. However, use is not established for patients with severe hepatic impairment.
  • Pregnancy/Lactation: Use during pregnancy or while breastfeeding is conditional, permitted only if considered clearly essential, as the drug is known to be excreted into human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Telekast (Montelukast Sodium) is structured based on documented changes in drug exposure and pharmacodynamic effects, as detailed in authoritative government regulatory sources.

Pharmacokinetic Interactions

Classification Interacting Agent Official Regulatory Outcome
Exposure Increase Gemfibrozil (CYP inhibitor) Increases the drug's total systemic exposure by approximately 4.4-fold.
Exposure Decrease Phenobarbital (CYP inducer) Decreases the drug's total systemic exposure by about 40%.
Caution Advised Phenytoin, Rifampicin (CYP inducers) Caution is noted in regulatory labels when co-administered due to potential for reduced drug levels.

Other Documented Interactions

  • Pharmacodynamic Augmentation: The bronchodilation effect produced by a beta-agonist is officially documented to be additive when used concurrently with Telekast.
  • Food Interaction: Ingestion with a high-fat meal is reported to reduce the maximum concentration of the drug in the blood, but the total amount absorbed remains unaffected.
  • Substance Interaction: Official guidance confirms that alcohol consumption is permitted while taking this medicine.
  • Formal Restrictions: No formal contraindicated combinations (prohibited pairings) are listed in the reviewed regulatory labels.

The product’s official interaction structure centers on managing pharmacokinetic changes, specifically the reported alterations in the total systemic exposure due to CYP enzyme modulation. This structure defines the circumstances where caution is advised based on the potential for increased or decreased drug levels.

Mechanism of Action

How Telekast Works

Molecular Antagonism of Leukotriene Signaling

Telekast (Montelukast Sodium) functions as a selective antagonist by binding to the Cysteinyl Leukotriene type-1 (CysLT1) receptor. This action competitively blocks the binding of the inflammatory eicosanoid Leukotriene D4 (LTD4), a key molecular step in the Arachidonic Acid cascade. By neutralizing the LTD4 action, the drug modulates molecular signaling within inflammatory and structural cells of the respiratory tract.

Modulating Airway and Vascular Response

The antagonistic action halts the cascade that otherwise drives specific physiological responses. This inhibits the contraction of airway smooth muscle and simultaneously reduces vascular permeability in the mucosal lining. The resulting physiological effect is a change in tissue state, which constrains the physical accumulation of edema and influences local resistance within the respiratory and nasal passages.

️ Sustained Modulation and Mechanistic Constraints

The drug's kinetic profile supports sustained modulation by continuously acting on the inflammatory pathway. This mechanism is physiologically ineffective in reversing immediate, sudden bronchospasm. Furthermore, the molecule crosses the blood-brain barrier, a factor that contributes to a mechanistic constraint involving off-target activity independent of the primary peripheral CysLT1 receptor antagonism.

Dosage and Administration Information

Telekast is administered orally and is available in film-coated tablets, chewable tablets, and oral granules. The administration follows a fixed-dose, once-daily pattern for chronic management. The standard regimen for adults and adolescents aged 15 years and older is 10 mg once daily. For children, the labeled dosing ranges from 4 mg to 5 mg once daily, depending on the specific age group. The medicine is intended for long-term, continuous daily use in maintenance therapy.

For chronic use, the daily dose is typically administered in the evening when the drug is used for asthma or a dual indication (asthma plus rhinitis). The medicine may be taken with or without food. If a daily dose is missed, the general practice is to skip the missed dose and resume the regular once-daily schedule, as the dose must never be doubled. Importantly, no dosage adjustments are generally required for older adult patients or those with renal impairment, nor for mild-to-moderate hepatic impairment.

Administration for the prevention of exercise-induced bronchoconstriction (EIB) follows an intermittent schedule, requiring a single dose to be taken at least two hours before exercise. Patients already on the daily maintenance dose should not take an additional dose for EIB prevention on the same day. Specific procedural rules apply to the oral granules, which must be consumed in their entirety, whether administered directly or mixed with specified soft foods or liquids, within 15 minutes of opening the sachet.

Recent Clinical Evidence

Telekast: Overview of Clinical Research

Research into Telekast (Montelukast) is based primarily on Randomized Controlled Trials (RCTs) and systematic reviews that explore its use in managing chronic respiratory and allergic conditions. These studies, often spanning from a few weeks to up to a year, evaluate the medicine's profile across different age groups, including adults, adolescents, and children (as young as 6 months for certain indications).

Asthma and Allergic Rhinitis

The research for persistent asthma focuses on outcomes related to systemic or functional imbalance, such as lung function (FEV1) and the required use of rescue medication. Findings describe patterns observed in studies where research reported measurements related to changes in these functional markers compared to placebo. When studied alongside standard inhaled corticosteroids (ICS), research highlights further measured changes in some subjects. Comparative evidence, however, suggests variations in measured outcomes related to overall asthma control when comparing Telekast monotherapy against ICS.

For allergic rhinitis (seasonal and perennial), short-term RCTs have monitored outcomes related to physical discomfort, such as changes in overall nasal symptom scores. While studies reported how symptoms evolved in the observed populations, systematic reviews report patterns suggesting that the magnitude of measured changes was often smaller compared to those typically reported for intranasal corticosteroids.

Research Gaps and Uncertainty

The evidence base is limited by the follow-up durations of controlled RCTs; therefore, long-term effects are not fully established for sustained use over many years. This restricts the available data on low-frequency events. Additionally, comparative evidence is sometimes lacking, and the subgroup findings are uncertain in specific populations, such as older adults with multiple chronic conditions. The certainty remains low for predicting outcomes in these less-studied groups.

Key Studies & References Montelukast Sodium. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury.

Frequently Asked Questions (FAQ)

Common questions about Telekast (FAQ)

Q: Is Telekast classified as a steroid medicine?

Official regulatory documents classify Telekast (Montelukast) as a leukotriene receptor antagonist (LTRA). This pharmacological class of medicine targets specific inflammatory chemicals in the body by blocking their activity. Telekast is not classified as a steroid medicine.

Q: How quickly can a person expect Telekast to start showing a noticeable effect?

Official product information indicates that the therapeutic effect on parameters of asthma control is often observed to begin within one day of starting the continuous daily treatment. This medicine is intended for sustained, long-term maintenance rather than providing immediate or rapid relief.

Q: How long does the therapeutic effect of one dose of Telekast typically last?

The active substance in Telekast has a mean plasma half-life that typically ranges from 2.7 to 5.5 hours. This pharmacokinetic profile, which describes how the body processes the drug, supports the medicine's once-daily administration for sustained action.

Q: Is drowsiness or feeling sleepy a known side effect of Telekast?

Sleepiness, or somnolence, has been reported in post-marketing experience outside of formal clinical trials. Other related neurological events, such as dizziness and insomnia (difficulty sleeping), are listed as documented adverse reactions in official safety information.

Q: Is it true that Telekast can cause unusual dreams or sleep disturbances?

Official safety information indicates that serious neuropsychiatric events have been reported in the post-marketing setting. These reports include dream abnormalities, such as nightmares and unusual dreams, as well as general sleep disturbances like insomnia.

Q: Does Telekast interact with any specific foods or fruit juices?

Regulatory documents note that ingesting the medicine with a high-fat meal can reduce the drug’s maximum concentration in the blood, though the total amount of medicine absorbed remains unchanged. No specific adverse interactions with fruit juices are documented in the official prescribing information.

Q: What are the warnings about mixing Telekast with specific seizure medications?

Caution is advised when Telekast is taken concurrently with certain medicines that affect liver enzymes, such as the seizure medications Phenobarbital or Phenytoin. These medicines can significantly decrease the total systemic exposure of Telekast, meaning less of the active substance is available in the body.

Q: Are there different forms of Telekast, such as chewable tablets or syrups?

Telekast is available in several forms for oral administration, including film-coated tablets, chewable tablets, and oral granules. A syrup formulation is not listed in the standard prescribing information from regulatory authorities.

Q: Are there any specific safety warnings for older adults taking Telekast?

Regulatory sources state that no dosage adjustment is generally required for older adult patients. However, the overall risk of neuropsychiatric events noted in the boxed warning applies to all age groups, and research evidence for outcomes in this specific population remains uncertain.

Q: Does taking Telekast reduce the need to carry a rescue inhaler?

Official warnings state that Telekast is not intended to treat acute asthma attacks. Official warnings note that having an appropriate short-acting beta-agonist rescue medication available is essential for managing acute episodes, regardless of daily use of Telekast.

Q: Is Telekast known to interact with common cold or flu medications?

Studies suggest there are no known major interactions between Telekast and common active ingredients found in many over-the-counter cold and flu preparations, such as acetaminophen or dextromethorphan. Official guidance emphasizes the importance of providing a complete list of all current medicines to a healthcare provider.

Q: Can Telekast be taken alongside common over-the-counter pain relievers?

It is generally considered safe to take common over-the-counter pain relievers with this medicine, according to regulatory guidance summaries. Official guidance advises that patients with aspirin-sensitive asthma typically continue to avoid aspirin and other non-steroidal anti-inflammatory agents.

Q: Is it necessary to stop Telekast before an allergy skin prick test?

Telekast (Montelukast) is a leukotriene receptor antagonist and is typically not required to be stopped before an allergy skin prick test. Antihistamines, which have a different mechanism of action, are usually the type of drug that needs to be discontinued prior to such a test.

Q: Is Telekast a type of medicine known as an antibiotic?

Telekast is classified as a leukotriene receptor antagonist (LTRA) and is used for the chronic management of inflammation in the airways and nasal passages. It is not an antibiotic medicine, which is used to treat bacterial infections.

Q: If symptoms improve, is it okay to stop taking Telekast abruptly?

Official guidance advises that taking the medicine should continue even if symptoms are under control, as it is a maintenance treatment. Regulatory warnings state that the medicine should not be abruptly substituted for inhaled or oral corticosteroids.

How should Telekast be stored and disposed of?

How to Store and Dispose of Telekast (Montelukast)

Official regulatory documents define specific conditions required for the storage and disposal of Telekast to ensure its stability and safety.

Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature (typically between 15 C and 30 C or below 25 C).
Protection Keep the medicine in the original package to protect from light and moisture.
Child Safety Keep out of the sight and reach of children and store locked up.
Stability Rule Oral granules must be administered immediately after opening the sachet or mixing with food (typically within 15 minutes). Unused mixtures must be discarded.

Disposal Instructions

Any unused or expired Telekast must be disposed of in accordance with local requirements for pharmaceutical waste. Do not dispose of the medicine via wastewater (such as flushing down the toilet) or general household trash unless local guidelines specify otherwise. Consumers are advised to utilize local drug take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Telekast found in:

A-Z Index: